The affected erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH II and PNH III cells) are abnormally sensitive to complement-mediated lysis. Normal human erythrocytes chemically modified by treatment with 2-amino-ethylisothiouronium bromide (AET) have been used as models for PNH cells inasmuch as they also exhibit an enhanced susceptibility to complement. To investigate the bases for the greater sensitivity of these abnormal cells to complement-mediated lysis, we compared binding of C3 and constituents of the membrane attack complex to normal, PNH II, PNH III, and AET-treated cells after classical pathway activation by antibody and fluidphase activation by cobra venom factor complexes. When whole serum complement was activated by antibody, there was increased binding of C3 and C9 to PNH II, PNH III, and AET-treated cells, although the binding of these complement components to PNH II and PNH III cells was considerably greater than their binding to the AET-treated cells. In addition, all of the abnormal cell types showed a greater degree of lysis per C9 bound than did the normal erythrocytes. PNH III and AET-treated cells were readily lysed by fluid-phase activation of complement, whereas normal and PNH II erythrocytes were not susceptible to bystander lysis. The greater hemolysis of PNH III and AET-treated cells in this reactive lysis system was due to a quantitative increase in binding of constituents of the membrane attack complex. This more efficient binding of the terminal components after fluid-phase activation of whole serum complement was not mediated by cell-bound C3 fragments. These investigations demonstrate that the molecular events that characterize the enhanced susceptibility of PNH II, PNH III, and AET-treated erythrocytes to complementmediated lysis are heterogeneous.
Introduction
The erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH)' have been classified into three subtypes according to their in vitro susceptibility to antibody-initiated complementmediated lysis (1, 2) : PNH I cells are normal (or nearly normal) in their susceptibility; PNH II cells are moderately sensitive to complement, requiring 25-33% as much serum (as the complement source) for an equal degree of lysis as normal erythrocytes; and PNH III cells are exquisitely sensitive to complement, requiring 4-7% as much serum for an equal degree of lysis compared to normal erythrocytes. Both PNH II and PNH III cells fix more complement (C)3b when complement is activated by either the classical or the alternative pathway (3) (4) (5) (6) . This greater binding of C3b is due to the enhanced functional activity of the C3 convertase when affixed to these abnormal cells. Enhanced convertase activity may be due to several different mechanisms inasmuch as the convertase (a) has greater enzymatic activity when affixed to PNH cells (7) , (b) forms more readily on PNH erythrocytes (7, 8) , and (c) is more stable when bound to the abnormal cell membrane (8, 9) . These aberrant interactions with complement appear to be related to abnormalities in glycoproteins of the cell surface, which function as regulators of the complement system (8) (9) (10) (11) . The greater activity of the C3 convertase is primarily responsible for the enhanced susceptibility of PNH II cells to complement-mediated lysis, because unlike PNH III cells they do not display a marked susceptibility to cytolysis in reactive lysis systems (6) .
Normal human erythrocytes can be made to manifest a susceptibility to complement lysis similar to that of PNH cells by in vitro modification that uses the sulfhydryl compound, 2-amino-ethylisothiouronium bromide (AET) (12) . Like PNH III erythrocytes, AET-treated erythrocytes are exquisitely sensitive to reactive lysis, as well as to lysis mediated by the classical and alternative pathways (12, 13) .
To define more clearly the molecular basis for the greater susceptibility of PNH II, PNH III, and AET-treated erythrocytes to complement-mediated lysis, we have compared the binding of C3, C7, C8, and C9 to these abnormal cells after classical pathway activation by antibody and fluid-phase activation by activated cobra venom factor complexes (CoFBb). These studies demonstrate that although there are areas of overlap at the phenotypic level, at the molecular level the aberrant interactions venom factor from Naja naja; CoFBb, activated cobra venom factor complexes prepared by incubating purified cobra venom factor with factor B and factor D; CR1, complement receptor type 1; GVB, veronal-buffered saline containing 0.1% gelatin; GVB+, GVB containing 5 mM magnesium; GVB++, GVB containing 0.5 mM magnesium and 0.15 mM calcium; PNH, paroxysmal nocturnal hemoglobinuria; TCP, trypsin cleavage peptide; VBS, veronal-buffered saline.
with complement are distinctive for each cell type. Abnormalities in erythrocyte membrane glycoproteins, which are regulators of the complement system, may mediate these aberrant interactions.
Methods
Human erythrocytes. Erythrocytes from normal donors and from patients with chronic cold agglutinin disease (CCAD) (14) and PNH (7) were prepared and stored as previously described. The PNH II cells were obtained from a patient with 93% type II and 7% type III cells, whereas the PNH III cells were obtained from a patient with -88% type III and 12% type I cells (1, 2) . Normal human erythrocytes treated with AET (Sigma Chemical Co., St. Louis, MO) were prepared according to the method of Sirchia et al. (12) using a 9-min incubation period.
Buffers. The following buffers were employed: Veronal-buffered saline, pH 7.5 (VBS); VBS containing 0.5 mM magnesium and 0.15 mM calcium (VBS++); VBS containing 0.1% gelatin (GVB); GVB containing 5 mM magnesium (GVB+); GVB containing 0.5 mM magnesium and 0.15 mM calcium (GVB++); GVB containing 15 mM ethylenendiamine tetraacetic acid (GVB-EDTA); Alsever's solution (7); and phosphate-buffered saline containing 150 mM sodium chloride and 10 mM sodium phosphate, pH 7.4. Complement components. Clq (15), C3 (7), C7 (16), C8 (17), C9 (18), cobra venom factor (CoF) (Naja naja) (19) , factor B (7), C3 nephritic factor (7) , and factor D (7) were isolated by using previously described methods. The purification of each protein was assessed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (20) , and functional activities were determined by hemolytic assay (21, 22) .
Complement-deficient sera. Human sera deficient in one or more of complement components C7, C8, and C9 were prepared by immunochemical depletion. Briefly, freshly drawn human serum containing 15 mM EDTA was prepared and applied to immunoaffinity columns of the appropriate goat monospecific antibody coupled to Affi-Gel 10 (Bio-Rad Laboratories, Richmond, CA). The breakthrough serum was pooled, reconstituted with Clq (70 ;tg/ml), dialyzed against VBS++, and stored in aliquots at -850C.
Antibodies. Monoclonal anti-C3c as ascites fluid (Bethesda Research Laboratories, Gaithersburg, MD) was purified as previously described (7) . Monoclonal anti-C3d (14) , anti-C3dg (14) , and anti-CR 1 (complement receptor type 1) (14) were gifts from Dr. Gordon D. Ross (University of North Carolina, Chapel Hill, NC). They were purified using 5% caprylic acid (Sigma Chemical Co.) (14) . The anti-C3d was further purified by adsorption and elution (using 4 M MgCI2) from an affinity column bearing C3d. The excess MgCl2 was removed by extensive dialysis. Monospecific polyclonal anti-human C7, C8, and C9 were raised in goats. The IgG fractions were isolated by using caprylic acid (22) .
Protein determination. Protein concentration for Clq (23), C7 (24), C8 (25), C9 (25), and IgG (14) were determined spectrophotometrically. Other protein determinations were made with the Bio-Rad protein assay (Bio-Rad Laboratories) by using bovine IgG as the standard.
Radiolabeling. C7 (2.19 and 9.30 X 101 cpm/Ag), C8 (2.44 X 10' cpm/ug), and C9 (2.11 X 101 cpm/sg) were labeled with either '"'I or 125I as Nal (Amersham Corp., Arlington Heights, IL) by using Enzymobeads (Bio-Rad Laboratories) without loss of functional activity, employing minor modifications of the manufacturer's suggested procedure. Anti-C3c (1.6 X 106 cpm/Ag), anti-C3d (1.2 X 10' cpm/Mg) anti-C3dg (1.4 X 106 cpm/Mg), and anti-CR 1 (1.1 X 106 cpm/.sg) were radiolabeled with 1251 using IODO-GEN (Pierce Chemical Co., Rockford, IL) as previously described (25).
Determination of cell-bound '25I-C8 and '31I-C9 after classical pathway activation of complement. Normal, PNH II, PNH III, and AET-treated erythrocytes were washed three times in GVB++ and resuspended to 5 X 108/ml in the same buffer. C8/C9-depleted serum was repleted by adding 1215148 and 131I-C9 to a final concentration of 50 and 70 Aig/ml respectively, and dilutions were prepared using GVB++. Seven reaction mixtures were prepared for each cell type. These mixtures contained 100 Ml of the appropriate cell suspension, 100 jl of various concentrations of '251I-C8/'3"I-C9-repleted serum, and 100 jl of a 1:100 dilution (in GVB++) of rabbit anti-human red blood cell antiserum (United States Biochemical Corp., Cleveland, OH). To maintain consistency, dilutions of the repleted serum were prepared as a separate pool in quantity sufficient to allow use with each set of cells in duplicate experiments. As controls for nonspecific binding of 125I1 C8 and 31I-C9, parallel reaction mixtures were prepared substituting GVB`+ for antibody. The reaction mixtures were incubated at 370C in a shaking water bath. After 30 min, 700 Ml of cold GVB-EDTA was added to each tube, and the reaction mixtures were transferred to 1.5-ml microfuge tubes and spun for 5 min at 12,000 rpm in a Beckman model 12 microfuge (Beckman Instruments, Inc., Fullerton, CA). The supernate was recovered, and the percent lysis was determined by measuring free hemoglobin release.
The cells were then resuspended to 100 Ml (5 X 108 cells/ml) with GVB-EDTA. Three 25-IAI aliquots were aspirated from each suspension and layered onto 200 Ml of 20% sucrose in 400-Ml polyethylene microfuge tubes (Analytical Laboratories, Rockville Centre, NY). The bound and unbound '25I-C8 and '31I-C9 were separated by spinning the tubes at 12,000 rpm for 10 min. The tubes were then cut just above the pellet. After determining the radioactivity of the pellet, the amount of cell-bound '25I-C8 and '3'I-C9 was calculated by using molecular weights of 151,000 for C8 (17) and 71,000 for C9 (18 12 ,000 rpm in the microfuge. The number of molecules of cell-bound '251-anti-C3d and '311-C9 were calculated as described above using 160,000 as the molecular weight of anti-C3d. Nonspecific binding was determined, and this value was subtracted in order to define specific binding.
Determination of cell-bound '25I-C8 and '1I-C9 after fluid-phase activation ofcomplement. Normal, PNH II, PNH III, and AET-treated cells were washed three times in GVB-EDTA and resuspended to 3.33 X 109/ml. Serum depleted of C8/C9 was repleted with 1251-C8 and '3'I-C9 as described above. The '251-C8/'3'I-C9-repleted serum containing 20 mM EDTA was prepared and incubated for 5 min at 37°C. Four, twofold falling dilutions of the EDTA-chelated serum were prepared using GVB-EDTA as the diluent. CoFBb were prepared as previously described (14) . In duplicate, 20 ,ul of each cell type was incubated with 100 M1 of the appropriate serum dilution and 20 Mul ofCoFBb complexes at 37°C. Controls for nonspecific binding of 25I-C8 and`11-C9 were reaction mixtures similar to those described above except that GVB-EDTA was substituted for CoFBb. After 30 min, 850 Ml of GVB-EDTA was added to each tube, and the reaction mixtures were transferred to 1.5-ml microfuge tubes. After spinning for 5 min at 12,000 rpm in the microfuge, the percent lysis and the number of molecules of '25I-C9 specifically bound per cell were determined as described above.
Determination of cell-bound '31I-C7 and 125IC8 after fluid-phase activation of complement. C7/C8-depleted serum was repleted by adding '31I-C7 and '25I-C8 to a final concentration of 50 ug/ml each.
The remainder of the experiment was similar to that described above for determination of cell-bound '25I-C8 and '31I-C9 after fluid-phase activation of complement by CoFBb. The molecular weight of C7 used for the calculation of specifically bound molecules per cell was 92,400 (24) .
Determination of cell-bound C3 after fluid-phase activation of complement. These experiments were performed as described above with the following modifications. AB' serum from a volunteer donor was used as the complement source. After the incubation period, the cells were washed three times in GVB-EDTA and resuspended to 200 !l (2.5 X 108/ml) in GVB-EDTA. The amount of specifically bound '25I-anti-C3d was determined as described above.
Determination of cell-bound C3c, C3dg, and CR1. PNH II, PNH III, and CCAD erythrocytes were washed in the appropriate buffer, and the number of molecules of cell-bound C3c, C3dg, and CR1 sites per cell were determined by using previously described methods (14) .
Determination of C3 and C7 binding to PNH III and CCAD erythrocytes after fluid-phase activation of whole serum complement.
PNH III and CCAD erythrocytes were washed three times in GVB-EDTA and resuspended to 3.33 X 109/ml. C7-repleted serum was prepared by adding '3'I-C7 to a final concentration of 50 ,g/ml followed by the addition of EDTA to a final concentration of 20 (26) . Using '251-C7 repleted serum, the percent hemolysis and the amount of C7 bound to normal EC3b and PNH III erythrocytes after fluid-phase activation of complement by CoFBb were determined by using the methods described above. SDS-PAGE of trypsinized and nontrypsinized normal, PNH II, PNH III, and AET-treated erythrocytes labeled with NaOI4/NaBH4.
These experiments were performed by using previously described methods (I 1).
Results
Profile of the complement sensitivity of normal, PNH I, PNH III, and AET-treated erythrocytes when whole serum complement is activated by antibody. Because of the pivotal role of C9 in complement-mediated cytolysis (27) To determine whether there were quantitative differences in the functional activity of the membrane attack complex on the abnormal cells, we compared C9 binding to lysis for the four cell types (Fig. 3 ). There was a dramatic difference in the amount of C9 required for a given degree of lysis for the normal erythrocytes compared to the abnormal cells. The mean±l SD, n = 3.
PNH III cells were the most sensitive with <2,500 C9 molecules being cell-bound at the 50% lysis point, whereas >70,000 molecules of C9 were associated with normal erythrocytes for the same degree of lysis. For PNH III and AET-treated cells, the binding of C7 was associated with a marked degree of cytolysis (Fig. 7) . As was the case with C9 binding, a very modest amount of C7 binding was associated with the lysis of a minor portion of the cells from the patient with predominantly PNH II erythrocytes. Normal erythrocytes bound no C7. The PNH III and AETtreated cells bound C7 with equal efficiency over the range of serum concentrations tested (Fig. 8 A) . Although C8 binding (Fig. 8 B) paralleled C7 binding, the ratio of '251-C8 to '31I-C7 was consistently less than unity, and this was particularly evident at higher serum concentrations. Fig. 8 C vs. A) . For example, when neat serum was employed in the experiments, the amount of C7 bound to PNH III erythrocytes was -10,500 molecules/cell whereas the amount of C3 fragments bound was -1,300 molecules/cell. Further, there was little difference between the amount of C3 fragments present on the PNH II erythrocytes (-400 molecules/cell when neat serum was used) compared to AET-treated cells (-650 molecules/cell); yet the chemically modified cells bound much more C7 ('12,000 molecules/ cell) and were readily lysed, whereas the PNH II cells bound little C7 (-700 molecules/cell) and were not susceptible to bystander lysis (Figs. 7 and 8, A and C) .
Erythrocytes from chronic cold agglutinin disease bind fluid-phase activated C3b more efficiently than normal erythrocytes (14) . To examine further whether cell-bound C3 plays a functional role in the cytolysis of human erythrocytes in a reactive lysis system, we quantified cell-bound C3c, C7, and percent lysis for CCAD and PNH III cells when whole serum complement was activated by CoFBb (Fig. 9) . Although the CCAD cells had three times more membrane bound C3c than the PNH III cells, the PNH III erythrocytes bound much more C7 than the CCAD erythrocytes. There was little lysis of the CCAD erythrocytes, whereas all of the abnormal PNH III cells were lysed under these experimental conditions.
Jones et al. (32) have suggested that PNH erythrocytes bear functionally active C3 fragments, which are responsible for their enhanced cytolysis in reactive lysis systems. For the PNH III erythrocytes, we found no cell-associated C3 fragments (Table I) . C3 fragments were associated with the PNH II cells (Table I ), yet these cells were not hemolyzed when whole serum complement was activated by cobra venom factor complexes (Fig. 4) . The CCAD erythrocytes bore large numbers of C3 fragments (Table I ), yet, as with the PNH II cells, they were not susceptible to reactive lysis (Fig. 9) . The low number of CR1 sites on PNH II and CCAD erythrocytes is an epiphenomenon associated with the activation and binding of C3 to the membrane (33) . This complement regulatory protein t Cell-bound C3dg was determined using "25I-monoclonal anti-C3dg;
<85 molecules/cells is within the normal range. § The number of CR1 sites was determined using monoclonal 1211_
anti-CR1; the range for normals is 145-1214 sites/cell and the mean is 643 (n = 125).
apparently plays no functional role in the modulation of reactive lysis, in that it is present in a normal number of copies on the PNH III cells (which are susceptible to reactive lysis) and deficient on PNH II and CCAD erythrocytes (which are insusceptible).
We also compared the binding of C7 to normal EC3b and to PNH III erythrocytes (Fig. 10 ). There was extremely modest binding of C7 to the normal EC3b, and these cells were virtually resistant to reactive lysis.
These data demonstrate that the greater binding of the components of the membrane attack complex to PNH III and AET-treated cells (and the consequent greater hemolysis of these abnormal cells) after fluid-phase activation of whole serum complement is not modulated by cell-bound C3 fragments.
Trypsin-mediated proteolysis of membrane glycoproteins on normal, PNH I, PNH III, and AET-treated erythrocytes.
We have recently demonstrated a qualitative abnormality in glycophorin-a (the major erythrocyte sialoglycoprotein) on PNH III erythrocytes (1 1). To determine whether glycophorina is abnormal on PNH II and AET-treated cells, as well as on PNH III erythrocytes, we compared the electrophoretic pattern of trypsinized and nontrypsinized membrane proteins from normal, PNH II, PNH III, and AET-treated erythrocytes after radiolabeling of the terminal sialic acid residues with NaIO4/ NaB3H4. The Coomassie Blue staining pattern among the four cell types was the same (data not shown). There were very subtle differences in the radiolabeling pattern of the untrypsin- (5, 6) . Because C5 convertase activity depends upon the presence of cell-bound C3b (34) , it follows that greater C3b binding would enhance C5 convertase activity, thereby favoring membrane attack complex formation. This is in keeping with our finding that the greater binding of C9 to PNH II and PNH III cells (Fig.  1) paralleled the greater binding of C3b (Fig. 2) . In these experiments in which whole serum complement was activated by antibody, PNH II cells bound slightly more C3b (-4.3 times more than normals) than did the PNH III cells (-3.5 times more than normals). This may be in part due to the fact that the PNH III cells were from a patient with 88% abnormal cells, whereas the PNH II cells were from a patient with 100% abnormal cells (93% type II and 7% type III). In addition, the PNH II cells were relatively deficient in CR1 whereas the PNH III cells were not ( Table I ). The AET-treated cells consistently bound more C3b than untreated normal cells (-1.7 times more) but considerably less than the abnormal PNH cells. The molecular basis for this greater binding of C3b to AET-treated cells is not delineated by these experiments. Both PNH III and AET-treated cells are susceptible to reactive lysis whereas PNH II cells (and normal erythrocytes) are not (6, 13) . These findings (along with others which will be discussed below) suggest that factors other than greater C3/C5 convertase activity mediate the enhanced susceptibility of PNH III and AETtreated cells to complement-mediated hemolysis. The greater lysis of these cells per C9 molecule bound (Fig. 3) (Fig. 3) . It seems likely that increased C3/C5 convertase activity not only results in a quantitative increase in C9 binding to the abnormal cell ( Fig. 1) , but also favors the formation of cytolytically effective complement lesions (Fig.  3) . The latter may be due to clustering of membrane attack complexes around the superactive convertase site, thus allowing individual complexes to coalesce or otherwise act in concert. At the molecular level, the resistance of normal and PNH II cells to reactive lysis is due, at least in part, to inhibition of binding of components of the membrane attack complex (Figs.  4-8) . However, the mechanism by which normal and PNH II cells resist binding of fluid-phase activated C5b-7 (and subsequent binding of C8 and C9) is not clear. In whole serum, fluid-phase inactivation of this trimolecular complex is accomplished by interactions of the labile binding site (associated with the C7 constituent [35] [36] [37] ) with the S protein, the C5b-7 inhibitor protein, and with other less well-characterized lipoproteins (38, 39) . One of the difficulties in speculating about how normal and PNH II cells inhibit binding of membrane attack complex components (whereas PNH III and AETtreated cells do not) is that little is known about the interactions of the labile binding site of C5b-7 with membrane constituents. The binding of the trimolecular complex is noncovalent, being mediated by exposure of the hydrophobic regions within the three molecules which allows for their insertion into the lipid bilayer of the cell. (43) .
The quantitative increase in binding of membrane attack complex components to PNH III and AET-treated cells after fluid-phase activation of complement by CoFBb complexes is not mediated by cell-bound C3 fragments (Figs. 8 C-10 and Table I ). Although PNH III cells bind slightly more C3 than PNH II, AET-treated, or normal cells, they bind very much greater amounts of C7 (and C8 and C9) than the normal or PNH II erythrocytes (Figs. 5, 6, 8 A and B) . Further, PNH II and AET-treated cells bind essentially the same amount of C3 after fluid-phase activation of complement (Fig. 8 C) , yet the AET-treated cells bind much more C7-9 (Figs. 5, 6, 8 A and B) . Our experiments that use CCAD erythrocytes, which bind fluid-phase-activated C3 more efficiently than normal erythrocytes (14) (Fig. 9) , and those that use normal EC3b (Fig. 10 ) also suggest that cell-bound C3 does not contribute significantly to hemolysis of human erythrocytes in reactive lysis systems.
We also quantified the presence of C3 fragments and CR1 receptor sites on PNH II, PNH III, and CCAD cells ex vivo (Table I ). The quantity of membrane-bound C3 fragments was within the normal range for PNH III cells whereas both PNH II and, to a much greater extent, CCAD erythrocytes bore abnormally large amounts of C3 fragments. It has been reported that inactivation of cell-bound C3b is impaired on PNH erythrocytes, due to deficient factor I cofactor activity on the abnormal cells (8) . For human erythrocytes, CR1 serves as the cofactor for the enzymatic cleavage of cell-bound C3b to iC3b and C3dg by factor I (44) (45) (46) (47) . The number of CR1 sites on PNH III cells was well within the normal range, whereas the PNH II and CCAD erythrocytes had extremely low numbers of CRI sites (Table I ). These experiments demonstrate that the greater binding of the components of the membrane attack complex to PNH III cells (and their consequent greater hemolysis) is not mediated by cell-bound C3 fragments nor by a quantitative deficiency of CR1.
The inordinate binding of components of the membrane attack complex to PNH III cells apparently does not occur when complement is activated on the cell surface by antibody, in that PNH II cells (which do not bind membrane attack complex constituents after fluid-phase activation of complement) bind more C9 than PNH III (or AET-treated) cells after classical pathway initiation of the complement cascade. In the case of antibody activation of complement, binding of the terminal components (C5b-9) appears to be directly related to C3/C5 convertase activity (Fig. 2) . There may be other fundamental differences between cytolysis mediated by a reactive lysis system and that initiated by classical pathway activation. For instance, the ratio of C9 to C8 per cell is different for the two systems. For PNH III cells, the ratio is -6.5:1 for antibody-mediated activation and approximately -3.5:1 for fluid-phase activation. In addition, cell type may also influence C9 to C8 ratios, as the normal cells, which were relatively resistant to antibody-mediated lysis, had a ratio of Either hypothesis could be supported by the results of our experiments with glycophorin digests (Fig. 1 1) . For (11) . Recent studies have suggested that glycophorin modulates both sensitivity of cells to reactive lysis (48) and alternative pathway activity (49) . If glycophorin regulates both C3 convertase activity and susceptibility to reactive lysis, then one could speculate that greater susceptibility to reactive lysis requires a more severe derangement of glycophorin structure than regulation of convertase functions, thus accounting for the differences between PNH II and PNH III cells.
In support of the hypothesis that PNH III cells have two membrane abnormalities, one could speculate that the abnormality in glycophorin is responsible for the greater susceptibility of PNH III cells to reactive lysis and that regulation of C3/C5 convertase activity is mediated by another membrane constituent (e.g., decay-accelerating factor [9, 10] ), which is dysfunctional on both PNH II and PNH III cells. The abnormality in glycophorin on PNH III cells appears to be related to the carbohydrate moiety of the molecule (1 1). Because glycophorin is the major erythrocyte sialoglycoprotein, the abnormalities in glycophorin may reflect a more global disturbance in glycosylation of membrane constituents, some of which may be important regulators of the functional activity of complement, whereas others (e.g., acetylcholinesterase [43] ) may not.
The chemical process by which AET transforms normal erythrocytes into complement-sensitive cells remains speculative, but disruption of membrane structural properties by reduction of disulphide bonds appears to be the most likely mechanism (50) . Although the fluorographic patterns of the radiolabeled AET-treated cells was the same as that of normals (Fig. 11, lane 10 compared with lane 9) , the glycophorin molecules of the chemically modified cells were relatively resistant to trypsin-mediated proteolysis (Fig. 11, lane 12  compared with lane 11) . These data suggest that AET modifies cellular constituents that are important for the maintenance of the three-dimensional orientation of these integral membrane glycoproteins, thereby modifying their susceptibility to trypsin.
The electrophoretic pattern of trypsinized AET-treated cells contrast sharply with that of the trypsinized PNH III cells (Fig. 11, lane 8 compared with lane 12 ), yet the two-cell types share a common mechanism for their markedly abnormal sensitivity to reactive lysis (they both bind large quantities of membrane attack complex constituents). There appear to be two plausible explanations for these seemingly disparate observations: (a) The abnormalities in glycophorin are an epiphenomenon, and the greater binding of membrane attack complex components to the two cell types is due to dysfunction of other membrane constituents. Different mechanisms for mediating this enhanced binding of the terminal components may exist and a unique mechanism could be operative for each cell-type. (b) The abnormalities in glycophorin do mediate the greater binding of membrane attack complex constituents. Abnormalities in glycosylation (PNH III cells) and treatment of cells with AET result in similar changes in the threedimensional orientation of glycophorin. This may be the common molecular abnormality underlying the enhanced binding of the terminal components.
AET-treated cells (and other types of chemically modified cells [43] ) have been used as models for investigating the membrane defects in PNH. Our studies demonstrate that AETtreated erythrocytes resemble PNH III cells in that they are more susceptible to reactive lysis (as a result of greater binding of the terminal components). AET-treated cells, however, fix less C3b than PNH III (or PNH II) cells after complement activation by antibody. Further, the marked difference in the trypsin-cleavage pattern of the glycophorin molecules for the AET-treated cells compared to the PNH cells raises the possibility that the molecular basis for the aberrant interactions of these chemically modified cells with complement may be different than for the PNH cells. Although AET-treated cells do provide an important model for studying complement interactions with human erythrocytes, they can no longer be considered a paradigm for the investigation of the molecular basis of the aberrant interactions of complement with PNH erythrocytes.
